Compound class:
Synthetic organic
Comment: Compound 21k was designed as an inhibitor of TRAF2 and NCK interacting kinase (TNIK) [1]. Inhibition of TNIK is proposed as a mechanism to combat dysregulated Wnt/β-catenin signalling in colorectal cancer.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
Potential off-target kinases include Flt4 (IC50 30 nM), Flt1 (IC50 191 nM), DRAK1 (IC50 441 nM) and Aurora A (IC50 517 nM) [1]. Compound 21k is active in vitro and produces antitumour activity in the HCT116 xenograft mouse model of colorectal cancer. |
Selectivity at enzymes | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|